Apart from ibrutinib, patients with M-CLL, devoid of TP53 aberrations and in good shape enough to tolerate FCR therapy, should still be excellent candidates for your latter, with the advantage remaining that this treatment method could be finished in six months even though ibrutinib should be taken indefinitely. This selection would be particularly